niacinamide has been researched along with Erythema in 20 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Erythema: Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our patient experienced a diffuse hyperkeratotic rash, hand-foot skin reaction, facial erythema, and stomatitis within three weeks of initiation of sorafenib." | 7.76 | Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib. ( Sahai, S; Swick, BL, 2010) |
| "A 60-year-old woman with recurrent papular and vesiculobullous lesions of erythema elevatum diutinum responded to treatment with 100 mg of oral niacinamide three times a day and 250 mg of tetracycline hydrochloride four times a day." | 7.66 | Erythema elevatum diutinum treated with niacinamide and tetracycline. ( Kohler, IK; Lorincz, AL, 1980) |
| "A patient with tuberculous meningitis developed a pellagra-like skin eruption after treatment with isoniazid." | 7.65 | Topically applied niacinamide in isoniazid-induced pellagra. ( Comaish, JS; Felix, RH; McGrath, H, 1976) |
| " Sorafenib and sunitinib are two of these novel agents, acting on tumour angiogenesis as well as on other key proliferative pathways; recently approved for the treatment of advanced kidney cancer, they may cause peculiar cutaneous, vascular and mucosal toxicities, including hand-foot skin reaction, skin rash, hypertension and GERD-like oesophagitis/gastritis." | 4.84 | Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. ( Bonomi, L; Imarisio, I; Paglino, C; Porta, C, 2007) |
| "Our patient experienced a diffuse hyperkeratotic rash, hand-foot skin reaction, facial erythema, and stomatitis within three weeks of initiation of sorafenib." | 3.76 | Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib. ( Sahai, S; Swick, BL, 2010) |
| "A 60-year-old woman with recurrent papular and vesiculobullous lesions of erythema elevatum diutinum responded to treatment with 100 mg of oral niacinamide three times a day and 250 mg of tetracycline hydrochloride four times a day." | 3.66 | Erythema elevatum diutinum treated with niacinamide and tetracycline. ( Kohler, IK; Lorincz, AL, 1980) |
| "A patient with tuberculous meningitis developed a pellagra-like skin eruption after treatment with isoniazid." | 3.65 | Topically applied niacinamide in isoniazid-induced pellagra. ( Comaish, JS; Felix, RH; McGrath, H, 1976) |
| "Sorafenib is a targeted drug specifically engineered to inhibit Raf serine/threonine kinases, which are part of the reticular activating system (RAS) oncogene pathway." | 1.35 | Cutaneous drug eruptions induced by sorafenib: a case series. ( Kung, EF; Maddox, JS; Petronic-Rosic, V; Sethi, A, 2008) |
| "The incidence of skin cancer continues to increase despite increased use of sunscreens, which are less effective at preventing immunosuppression than sunburn." | 1.35 | UV radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide. ( Barnetson, RS; Damian, DL; Halliday, GM; Park, J; Patterson, CR; Stapelberg, M, 2008) |
| " We report the development of localized palmar-plantar epidermal hyperplasia, a rare but significant cutaneous adverse event from sorafenib therapy." | 1.34 | Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. ( Beldner, M; Burges, GE; Chaudhary, UB; Dewaay, D; Jacobson, M; Maize, JC, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (30.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akakpo, AS | 1 |
| Saka, B | 1 |
| Teclessou, JN | 1 |
| Mouhari-Toure, A | 1 |
| Moise Elegbede, Y | 1 |
| Kombate, K | 1 |
| Tchangai-Walla, K | 1 |
| Pitche, P | 1 |
| Ogawa, K | 1 |
| Fukumoto, T | 1 |
| Yoshida, M | 1 |
| Matsumoto, Y | 1 |
| Shobatake, C | 1 |
| Asada, H | 1 |
| Cicek, D | 1 |
| Kandi, B | 1 |
| Dagli, FA | 1 |
| Karaoglu, A | 1 |
| Haligur, BD | 1 |
| Maddox, JS | 1 |
| Kung, EF | 1 |
| Petronic-Rosic, V | 1 |
| Sethi, A | 1 |
| Lipworth, AD | 1 |
| Robert, C | 1 |
| Zhu, AX | 1 |
| Tanabe, K | 1 |
| Amoh, Y | 1 |
| Mii, S | 1 |
| Eto, H | 1 |
| Iwamura, M | 1 |
| Katsuoka, K | 1 |
| Sahai, S | 1 |
| Swick, BL | 1 |
| Rübsam, K | 1 |
| Flaig, MJ | 1 |
| Ruzicka, T | 1 |
| Prinz, JC | 1 |
| Dasanu, CA | 1 |
| Alexandrescu, DT | 1 |
| Dutcher, J | 1 |
| Damian, DL | 1 |
| Patterson, CR | 1 |
| Stapelberg, M | 1 |
| Park, J | 1 |
| Barnetson, RS | 1 |
| Halliday, GM | 1 |
| Beldner, M | 1 |
| Jacobson, M | 1 |
| Burges, GE | 1 |
| Dewaay, D | 1 |
| Maize, JC | 1 |
| Chaudhary, UB | 1 |
| Porta, C | 1 |
| Paglino, C | 1 |
| Imarisio, I | 1 |
| Bonomi, L | 1 |
| Pérez-Bernal, A | 1 |
| Moreno-Giménez, JC | 1 |
| Sotillo-Gago, I | 1 |
| Camacho-Martínez, F | 1 |
| Kohler, IK | 1 |
| Lorincz, AL | 1 |
| Comaish, JS | 1 |
| Felix, RH | 1 |
| McGrath, H | 1 |
| Yourick, JJ | 2 |
| Dawson, JS | 1 |
| Mitcheltree, LW | 2 |
| Clark, CR | 1 |
| Schmutz, JL | 1 |
| Cuny, JF | 1 |
| Trechot, P | 1 |
| Weber, M | 1 |
| Beurey, J | 1 |
| Seidel, K | 1 |
| Eckstein, M | 1 |
| Ionescu, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Re-validating Prophylactic Efficacy of Urea-based Cream on Sorafenib-induced Hand-foot Skin Reaction in Patients With Advanced Hepatocellular Carcinoma[NCT04568330] | 129 participants (Actual) | Interventional | 2014-03-21 | Completed | |||
| "Evaluation of the Restorative Efficacy of the Cosmetic Product Onco-Repair vs. Placebo on Grade 2 Hand Foot Syndrome Induced by Targeted Therapies or Conventional Chemotherapy. Randomized, Multicentre, Double Blind, Controlled Study Versus Placebo."[NCT03612011] | Phase 3 | 72 participants (Actual) | Interventional | 2018-07-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for niacinamide and Erythema
| Article | Year |
|---|---|
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses | 2009 |
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses | 2009 |
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses | 2009 |
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses | 2009 |
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.
Topics: Acneiform Eruptions; Antineoplastic Agents; Benzenesulfonates; Erythema; Esophagitis; Exanthema; Hum | 2007 |
18 other studies available for niacinamide and Erythema
| Article | Year |
|---|---|
Pellagra and pellagra-like erythema in a hospital setting in Lomé, Togo : retrospective study from 1997 to 2017.
Topics: Alcoholism; Diarrhea; Erythema; Female; Humans; Male; Malnutrition; Middle Aged; Niacinamide; Pellag | 2019 |
Eosinophilic annular erythema in a patient with autoimmune pancreatitis: Nicotinamide therapy may be beneficial for achieving remission.
Topics: Aged; Eosinophilia; Erythema; Humans; Male; Niacinamide; Pancreatitis; Skin Diseases, Genetic; Vitam | 2016 |
Localized palmar-plantar epidermal hyperplasia associated with use of sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema; Humans; K | 2008 |
Cutaneous drug eruptions induced by sorafenib: a case series.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Female; Humans; Mid | 2008 |
Non-pigmenting fixed drug eruption induced by sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Drug Eruptions; Eryth | 2010 |
Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Erythema; Humans; Kidney Neoplasms; Male; Middle Aged; Nia | 2010 |
Erythema marginatum hemorrhagicum: a unique cutaneous side effect of sorafenib.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Erythema; Hemorrhage; Humans; Liver Neoplasms; M | 2011 |
Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.
Topics: Acrodermatitis; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Erythema; Humans; K | 2007 |
UV radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide.
Topics: Administration, Topical; Adult; Apoptosis; Complement System Proteins; Energy Metabolism; Erythema; | 2008 |
Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema; Hu | 2007 |
[Erythema elevatum et diutinum treated with nicotinamide and tetracyclines].
Topics: Erythema; Humans; Male; Middle Aged; Niacinamide; Tetracycline | 1983 |
Erythema elevatum diutinum treated with niacinamide and tetracycline.
Topics: Drug Therapy, Combination; Erythema; Female; Humans; Middle Aged; Niacinamide; Recurrence; Tetracycl | 1980 |
Topically applied niacinamide in isoniazid-induced pellagra.
Topics: Administration, Topical; Adult; Erythema; Humans; Isoniazid; Male; Niacinamide; Pellagra; Tuberculos | 1976 |
Sulfur mustard-induced microvesication in hairless guinea pigs: effect of short-term niacinamide administration.
Topics: Animals; Blister; Enzyme Activation; Erythema; Guinea Pigs; Male; Mustard Gas; NAD; Niacinamide; Pol | 1992 |
Niacinamide pretreatment reduces microvesicle formation in hairless guinea pigs cutaneously exposed to sulfur mustard.
Topics: Animals; Biopsy; Edema; Erythema; Guinea Pigs; Male; Mustard Gas; NAD; Niacinamide; Skin | 1991 |
[Drug-induced pellagroid erythema. A case of pellagroid erythema caused by isoniazide].
Topics: Antineoplastic Agents; Erythema; Ethionamide; Female; Humans; Isoniazid; Middle Aged; Monoamine Oxid | 1987 |
[Testing of the antiphlogistic effect of antirheumatic drugs].
Topics: Antipyrine; Arthritis, Rheumatoid; Drug Synergism; Erythema; Humans; Injections, Intramuscular; Niac | 1966 |
[Vascular erythematous reaction by administration of vitamin PP (nicotinic acid). Demonstration of a pre- and post-clinical luetic roseola].
Topics: Drug Eruptions; Erythema; Humans; Niacinamide; Syphilis, Cutaneous | 1966 |